{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:03:38Z","timestamp":1780092218379,"version":"3.54.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.japh.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T16:40:06Z","timestamp":1551717606000},"page":"432-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Kazuhiko","family":"Kido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2019.01.014_bib1","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 American College of Cardiology Foundation\/American Heart Association guideline for the management of heart failure","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiole"},{"key":"10.1016\/j.japh.2019.01.014_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A\u00a0reappraisal of loop diuretic choice in heart failure patients","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.japh.2019.01.014_bib3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jacc.2012.12.043","article-title":"Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?","volume":"61","author":"Bikdeli","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cosin","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.japh.2019.01.014_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","article-title":"Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.japh.2019.01.014_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1388-9842(03)00150-8","article-title":"Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV\u2014efficacy and quality of life","volume":"5","author":"Muller","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.japh.2019.01.014_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.amjcard.2015.10.059","article-title":"Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial)","volume":"117","author":"Mentz","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.108.125278","article-title":"Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure","volume":"53","author":"Lopez","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.japh.2019.01.014_bib9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jacc.2007.04.080","article-title":"Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure","volume":"50","author":"Lopez","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type 1 turnover in chronic heart failure","volume":"43","author":"Lopez","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.clinthera.2011.08.006","article-title":"Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded\u2013end point, active-controlled study","volume":"33","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.japh.2019.01.014_bib12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/hrt.2005.079764","article-title":"Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.japh.2019.01.014_bib13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.jacc.2004.09.009","article-title":"Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure","volume":"44","author":"Tsutamoto","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","article-title":"Bioavailability, pharmacokinetics and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure","volume":"57","author":"Vargo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.japh.2019.01.014_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FJC.0000000000000212","article-title":"Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital","volume":"65","author":"Mentz","year":"2015","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.japh.2019.01.014_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.japh.2019.01.014_bib17","series-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011)","year":"2011"},{"key":"10.1016\/j.japh.2019.01.014_bib18","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.japh.2019.01.014_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/fca.15.56","article-title":"Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial","volume":"11","author":"Mentz","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00019053-200119060-00006","article-title":"Torsemide: a pharmacoeconomic review of its use in chronic heart failure","volume":"19","author":"Young","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.japh.2019.01.014_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00019053-200017050-00002","article-title":"Healthcare costs of patients with heart failure treated with torsemide or furosemide","volume":"17","author":"Stroupe","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.japh.2019.01.014_bib22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0149-2918(99)80007-1","article-title":"A\u00a0pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure","volume":"21","author":"Noe","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.japh.2019.01.014_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/fca.12.54","article-title":"Should torsemide be the loop diuretic of choice in systolic heart failure?","volume":"8","author":"DiNicolantonio","year":"2012","journal-title":"Future Cardiol"},{"key":"10.1016\/j.japh.2019.01.014_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00541464","article-title":"Torsemide, a new potent diuretic. Double-blind comparison with furosemide","volume":"31","author":"Broekhuysen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.japh.2019.01.014_bib25","first-page":"180","article-title":"Comparative pharmacodynamics of torsemide and furosemide in patients with oedema","volume":"38","author":"Herchuelz","year":"1988","journal-title":"Arzneimittelforschung"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911930024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911930024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:25Z","timestamp":1761543985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431911930024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S154431911930024X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2019.01.014","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}